SRZN — Surrozen, Inc./DE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1824893 ·
Last close
$29.54
Market Cap
$347.20M
52W High
$37.83
52W Low
$11.39
ADV30
614,203
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,000,000 | — | -10,370,000 | 50,177,000 | 115,606,000 | 102,039,000 | 334,271,000 |
| Mar 2026 | 5,000,000 | — | -10,456,000 | -127,505,000 | 120,709,000 | 106,910,000 | 398,856,000 |
| Dec 2025 | 528,000 | — | -12,639,000 | -183,159,000 | 98,726,000 | 89,245,000 | 286,488,000 |
| Sep 2025 | 983,000 | — | -10,885,000 | -71,643,000 | 94,046,000 | 81,335,000 | 117,561,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,762,000
Investing CF
$-222,000
Financing CF
$46,580,000
CapEx
$-222,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-17.87
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-604,613,000
Inventory
—
Receivables
$5,000,000
ST Investments
—
EBIT TTM
$-44,350,000
Pretax Income TTM
$-332,130,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$11,511,000
EBITDA
$-44,128,000
Free Cash Flow
$-21,751,750
Enterprise Value
$127,594,600
Total Cash
$102,039,000
Total Debt
$6,316,000
Shares Out
11,753,558
Trailing EPS
$-40.06
Book Value
$-18.60
ROE
—
ROA
-25.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,477,000 | -42,092,000 | -242,026,000 | 98,726,000 | 286,488,000 | -187,762,000 | -30,244,000 |
| Dec 2024 | 10,655,000 | -25,539,000 | -63,564,000 | 48,467,000 | 69,847,000 | -21,380,000 | -17,628,000 |
| Dec 2023 | 0 | -43,028,000 | -43,042,000 | 46,080,000 | 8,145,000 | 37,935,000 | -40,363,000 |
| Dec 2022 | 12,500,000 | -44,339,000 | -36,004,000 | 89,435,000 | 13,434,000 | 76,001,000 | -44,145,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.19
Max Pain — expiry 2026-10-16
max pain strike: $25.00 · spot: $29.86 · call oi: 336 · put oi: 1,876
Expected Move to 2026-10-16:
±$7.90
(26.46%) —
implied range
$21.96 –
$37.76
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCGN | Ocugen, Inc. | $345.89M | $1.02 | — |
| CABA | Cabaletta Bio, Inc. | $350.96M | $2.07 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $341.74M | $6.99 | — |
| PROK | PROKIDNEY CORP. | $334.28M | $1.60 | — |
| CCCC | C4 Therapeutics, Inc. | $366.61M | $2.98 | — |
News headlines (Yahoo Finance, 1h cache)
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
2026-09-08 12:30 · Yahoo
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 20:05 · Yahoo
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
2026-07-22 20:02 · Yahoo
We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate
2026-05-17 14:17 · Yahoo
Surrozen to Present at Upcoming Healthcare Investor Conference
2026-05-12 20:05 · Yahoo
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 20:05 · Yahoo
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-28 20:05 · Yahoo
Surrozen to Present at Upcoming Healthcare Investor Conferences
2026-09-02 20:05 · Yahoo
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
2026-04-15 11:06 · Yahoo
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
2026-04-14 13:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.